News Decision-Making Support

NCCN Guidelines to Be Integrated Into OpenEvidence's Medical AI Platform

The National Comprehensive Cancer Network (NCCN) has entered into a licensing agreement with OpenEvidence that would make the NCCN Clinical Practice Guidelines in Oncology accessible through OpenEvidence's AI–powered medical platform.

November 07, 2025 By ASCO AI Staff 2 min read
Share

5 Key Takeaways

  • 1

    NCCN has licensed its Clinical Practice Guidelines in Oncology to OpenEvidence's AI-powered medical platform.

  • 2

    The collaboration aims to enhance access to trusted cancer care recommendations using artificial intelligence.

  • 3

    NCCN guidelines will be integrated into OpenEvidence's platform for improved clinical decision-making support.

  • 4

    This partnership will enable faster access to quality diagnostic and treatment recommendations for clinicians.

  • 5

    OpenEvidence is the fastest-growing clinical decision support platform in the U.S., partnering with various medical organizations.

ASCO AI in Oncology is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. For more information, see Policies.

KOL Commentary
Watch

Related Content